Navigation Links
TGen and Scottsdale Healthcare researchers discover microRNA role in brain metastasis

PHOENIX, Ariz. March 31, 2011 Conducting genetic profiles using microRNA can help doctors predict which lung cancer patients are likely to also develop brain metastasis (BM), according to a study published today by Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).

The study identified microRNA-328 as a potential therapeutic target because of its association with the spread of cancer to the brain in patients with non-small cell lung cancer (NSCLC). NSCLC makes up 88 percent of the 222,000 annual U.S. cases of lung cancer, which is by far the most common of all cancers among Americans.

"This is one of the first studies using microRNA to identify lung cancer patients at risk for developing or likely to have brain metastasis," said Dr. Glen Weiss, the paper's senior author and Director of Thoracic Oncology at TGen Clinical Research Services at Scottsdale Healthcare. TCRS is a partnership between TGen and Scottsdale Healthcare that helps bring new therapies quickly to patients at the Virginia G. Piper Cancer Center in Scottsdale.

The paper, MicroRNA-328 is associated with non-small cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration, was published online today (March 31, 2011) by the International Journal of Cancer.

MicroRNAs are single-stranded RNA molecules that regulate how genes and proteins control cellular development. Because microRNAs are so resilient, they are relatively easy to detect in tumor tissue and blood, which is often a limitation for other biomarkers. In addition, one microRNA can regulate hundreds of genes.

"Previous efforts to characterize patients that will develop brain metastasis have been fairly disappointing," said Dr. Weiss. BM can cause neurologic, cognitive and emotional difficulties. "The ability to identify patients at risk for developing brain metastasis may lead to new prophylactic intervention that may mitigate morbidity and mortality."

Brain metastasis can cause severe side effects. Currently, brain metastasis is often identified on imaging scans when a lung cancer patient develops unexplained neurological symptoms. Then treatment often includes either surgery and/or radiation. There are no measures in place today to minimize risk. By using microRNA-328 as a biomarker, physicians might one day be able to identify patients most likely to benefit from earlier treatments such as prophylactic cranial irradiation, a strategy used in another type of lung cancer called small cell lung cancer.

The study used tumor specimens from Scottsdale Healthcare and University of Iowa Hospitals and Clinics. Over-expression of microRNA-328 resulted in an increase in cancer cell migration, the study said.

"The elevated expression of microRNA-328 in both thoracic and brain NSCLC samples suggests this microRNA may be involved in 'brain-seeking' metastatic potential," said Dr. Shilpi Arora, staff scientist at TGen and the paper's first author.


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related biology technology :

1. MedTrust Online and Scottsdale Clinical Research Institute at Scottsdale Healthcare Announce Collaboration to Provide Cutting Edge Technology to Improve Patient Care
2. Lexicon Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference
3. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
4. VIVUS to Present at the 10th Annual Needham Healthcare Conference
5. DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011
6. MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference
7. Amgen to Present at the Cowen and Company 31st Annual Healthcare Conference
8. Savient Pharmaceuticals to Present at the Citi 2011 Global Healthcare Conference
9. Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposium™
10. Sensus Healthcare Announces the Formation of a Medical Advisory Board
11. Shionogi-ViiV Healthcare Starts Phase III Trial for 572-Trii Fixed-Dose Combination HIV Therapy
Post Your Comments:
(Date:10/12/2017)... , ... October 12, 2017 ... ... has launched Rosalind™, the first-ever genomics analysis platform specifically designed for life ... Named in honor of pioneering researcher Rosalind Franklin, who made a major ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... today it will be hosting a Webinar titled, “Pathology is going digital. Is ... , on digital pathology adoption best practices and how Proscia improves lab economics ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
(Date:10/10/2017)... research firm Parks Associates announced today that Tom Kerber ... Annual Meeting , October 11 in Scottsdale, Arizona . ... how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the ...
Breaking Biology Technology:
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/17/2017)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... 2016 Annual Report on Form 10-K on Thursday April 13, 2017 ... ... Investor Relations section of the Company,s website at  under ... . 2016 Year Highlights: ...
Breaking Biology News(10 mins):